
Intersect ENT, Inc. XENT
Intersect ENT, Inc. Deferred Revenue 2011-2026 | XENT
Deferred revenue is the amount of money or obligations that a company has received in advance for goods or services that have not yet been delivered or performed. In other words, it is income that has already been received but has not yet been recognized in accounting as revenue because the goods or services have not yet been transferred to the customer.Features of the metric
- Sources of future cash inflows
A high level of deferred revenue indicates that the company has secured future cash flows, which positively affects forecasts of its financial condition and stability. - Assessment of operational stability
Deferred revenue reflects demand for the company’s products or services and its ability to attract customers willing to pay in advance. It is one of the indicators of business stability and its competitive advantages. - Risks and obligations
Although deferred revenue indicates future inflows, it also represents obligations that the company must fulfill. If fulfilling these obligations is delayed or impossible, it can negatively impact reputation and financial results. - Analysis of liquidity and cash flow
Inflows in the form of deferred revenue improve the company’s current liquidity since the funds are already in the accounts. However, investors need to assess the ratio of deferred revenue to fulfilled obligations to understand the actual financial capabilities and risks. - Impact on company valuation
In fundamental analysis, deferred revenue is taken into account for accurate revenue and profit forecasting, especially in industries with long-term contracts or subscriptions (e.g., IT sector, services, manufacturing).
Annual Deferred Revenue Intersect ENT, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | 137 K | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 137 K | 137 K | 137 K |
Deferred Revenue of other stocks in the Medical devices industry
| Issuer | Deferred Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
BIOLASE
BIOL
|
2.45 M | - | -13.19 % | $ 166 K | ||
|
GenMark Diagnostics, Inc.
GNMK
|
508 K | - | - | $ 1.77 B | ||
|
AdaptHealth Corp.
AHCO
|
59.8 M | $ 13.08 | 2.19 % | $ 1.77 B | ||
|
Allied Healthcare Products
AHPI
|
563 K | - | 3.58 % | $ 2.21 M | ||
|
BioSig Technologies
BSGM
|
16 K | - | 37.08 % | $ 85.7 M | ||
|
Aziyo Biologics
AZYO
|
533 K | - | 1.37 % | $ 20.5 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
424 K | - | -5.86 % | $ 30.6 M | ||
|
Cardiovascular Systems
CSII
|
2.11 M | - | 0.15 % | $ 844 M | ||
|
Conformis
CFMS
|
215 K | - | - | $ 16.4 M | ||
|
Dynatronics Corporation
DYNT
|
150 K | - | 14.99 % | $ 929 K | ||
|
Cytosorbents Corporation
CTSO
|
182 K | $ 0.61 | -2.58 % | $ 38 M | ||
|
Apollo Endosurgery
APEN
|
88 K | - | - | $ 475 M | ||
|
EDAP TMS S.A.
EDAP
|
3.41 M | $ 3.22 | - | $ 121 M | ||
|
ClearPoint Neuro
CLPT
|
1.67 M | $ 11.21 | -4.84 % | $ 317 M | ||
|
Globus Medical
GMED
|
27.7 M | $ 93.7 | -1.24 % | $ 12.7 B | ||
|
Eargo
EAR
|
621 K | - | - | $ 10.2 M | ||
|
CryoLife, Inc.
CRY
|
1.45 M | - | -4.14 % | $ 702 M | ||
|
Second Sight Medical Products
EYES
|
335 K | - | -0.97 % | $ 54.4 M | ||
|
Helius Medical Technologies
HSDT
|
148 K | $ 2.12 | -1.85 % | $ 1.29 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
33 | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
732 K | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
13.3 K | - | - | $ 462 M | ||
|
Butterfly Network
BFLY
|
16.1 M | $ 5.48 | 2.81 % | $ 1.16 B | ||
|
Delcath Systems
DCTH
|
170 K | $ 10.84 | - | $ 388 M | ||
|
LivaNova PLC
LIVN
|
11.5 M | $ 63.41 | -1.23 % | $ 3.46 B | ||
|
IRIDEX Corporation
IRIX
|
2.16 M | $ 1.08 | 1.89 % | $ 18.3 M | ||
|
LENSAR
LNSR
|
2.6 M | $ 5.21 | 2.36 % | $ 62.3 M | ||
|
Pulmonx Corporation
LUNG
|
18 K | $ 1.28 | 0.79 % | $ 52.1 M | ||
|
Integer Holdings Corporation
ITGR
|
5.21 M | $ 85.35 | -0.78 % | $ 2.96 B | ||
|
Invacare Corporation
IVC
|
2.28 M | - | - | $ 24.7 M | ||
|
NanoVibronix
NAOV
|
175 K | - | - | $ 1.08 M | ||
|
Myomo
MYO
|
2.51 K | $ 0.83 | 0.8 % | $ 34.7 M | ||
|
Cutera
CUTR
|
10.4 M | - | -10.19 % | $ 1.99 M | ||
|
Natus Medical Incorporated
NTUS
|
25.1 M | - | 1.94 % | $ 1.05 B |